The Ministry of industry and information technology informed these pharmaceutical companies to be named!

On November 18, the Ministry of industry and information technology issued the announcement of the construction unit of the second batch of small drug (short drug) centralized production base According to the publicity content, there are three consortia to be determined as the construction unit of the second batch of small drug (short drug) centralized production base The publicity time is from November 18, 2019 to November 22, 2019 The list is as follows: At present, there are more than 200 kinds of 3200 kinds of commonly used drugs with a large increase, focusing on some drugs in short supply, emergency (rescue) drugs and a few over-the-counter drugs It is reported that clofazimine used for MDR-TB treatment has been out of stock for more than one year, and at least 20000 patients' medication has been affected; as a commonly used blood tumor drug, cytarabine has been out of stock, and the drug has been in short supply worldwide since January 2019 Since the beginning of 2019, the price of common drugs such as nitroglycerin has increased or even been out of stock We can find that many of the shortages are often cheap and commonly used drugs These drugs are cheap and effective, and have a good reputation in basic medical institutions and patients Such as nifedipine, allopurinol, cedilanidine, etc However, in recent years, there have been many shortages, price increases and production stops of these effective and cheap common drugs The shortage or shortage of cheap and commonly used drugs is caused by many factors At the level of production, some APIs have strong seasonal supply, or the market concentration is high and easy to be controlled; or some drugs have small market capacity and small clinical demand but can not be replaced; or some drugs have relatively high technical threshold and are difficult to be involved by other enterprises in a short period of time At the market level, the profit space of cheap drugs is small, and commercial companies and distribution enterprises generally do not value these varieties In addition, the cost of APIs and production of many cheap drugs has increased, further reducing their profit margin The main problem is the low price Due to the small profit space, the enthusiasm of practitioners in the whole process is not high In addition to the three consortia publicized above, on January 28 this year, the Ministry of industry and information technology has released the list of the construction units of the first batch of concentrated production bases of small drug varieties (short drugs) The first three bases are: a consortium led by Shanghai Pharmaceutical Group Co., Ltd., organized and implemented by Shangyao Xinyi Pharmaceutical Co., Ltd and 23 enterprises; a consortium led by China Pharmaceutical Group Co., Ltd., organized and implemented by Shanghai Modern Pharmaceutical Co., Ltd and China Biotechnology Co., Ltd.; a consortium led by Chengdu Beite Pharmaceutical Co., Ltd The consortium established by Chengdu Beite Pharmaceutical Co., Ltd and Chongqing Yaoyou Pharmaceutical Co., Ltd are organized and implemented by 9 enterprises.